Analyst Price Targets — SNN
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| May 11, 2026 11:34 am | — | Bernstein | $31.85 | $29.95 | TheFly | Smith & Nephew price target lowered to $31.85 from $36.20 at Bernstein |
| May 11, 2026 11:09 am | — | Canaccord Genuity | $30.00 | $29.95 | TheFly | Smith & Nephew price target lowered to $30 from $32 at Canaccord |
| April 24, 2026 11:14 am | Caitlin Cronin | Canaccord Genuity | $32.00 | $31.92 | TheFly | Smith & Nephew price target lowered to $32 from $35 at Canaccord |
| October 14, 2025 10:53 am | — | Bernstein | $37.50 | $35.21 | TheFly | Smith & Nephew downgraded to Market Perform from Outperform at Bernstein |
| August 18, 2025 10:44 am | Caitlin Cronin | Canaccord Genuity | $36.00 | $36.54 | TheFly | Smith & Nephew price target raised to $36 from $28 at Canaccord |
| November 4, 2024 12:43 pm | Kyle Rose | Canaccord Genuity | $27.00 | $25.28 | StreetInsider | Smith & Nephew (SNN) PT Lowered to $27 at Canaccord Genuity |
Latest News for SNN
SNN launches the LYNX COBLATION Laryngeal Wand, combining precise dissection, rapid debulking and hemostasis for airway procedures.
Smith+Nephew (LSE: SN, NYSE: SNN), the global medical technology company, today announces the publication by expert clinicians of new consensus-based guidance - developed by them for the use of single-use negative pressure wound therapy (sNPWT) in closed surgical incisions. The guidance is supported by practical clinical practice recommendations for Germany and has been published in the internationally recognised…
Smith+Nephew (LSE: SN, NYSE: SNN), the global medical technology company, today announces the publication of new consensus-based guidance - developed independently by expert clinicians for the use of single-use negative pressure wound therapy (sNPWT) in closed surgical incisions. The guidance is supported by practical clinical practice recommendations for Germany. Published in internationally recognised journal of…
Smith & Nephew continues to demonstrate solid business recovery, with robust revenue, profit, and free cash flow growth across all divisions. SNN's 2026 outlook targets 6% underlying revenue growth, 8% organic trading profit growth, and $800 million in free cash flow, with a new $500 million share buyback announced. Completion of the 12-point plan delivered mixed results: revenue growth targets were met, but trading…
Smith & Nephew plc (SNN) Shareholder/Analyst Call Transcript
🧮 Earnings Move Analyzer
Insider Trading
No insider trades found for SNN.
Senate Trading
No Senate trades found for SNN.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.